Advertisement

Breast Cancer Research and Treatment

, Volume 155, Issue 3, pp 559–567 | Cite as

Associations of sex steroid hormones with mortality in women with breast cancer

  • Catherine DugganEmail author
  • Frank Stanczyk
  • Kristin Campbell
  • Marian L. Neuhouser
  • Richard N. Baumgartner
  • Kathy B. Baumgartner
  • Leslie Bernstein
  • Rachel Ballard
  • Anne McTiernan
Epidemiology

Abstract

Epidemiological studies have demonstrated associations between circulating levels of sex steroid hormones and risk of breast cancer in postmenopausal women. However, data on associations with breast cancer survival are limited. We measured levels of estradiol, estrone, testosterone, and sex hormone-binding globulin (SHBG), in serum collected on average 30 months after diagnosis from 358 postmenopausal women diagnosed with stage I-IIIA breast cancer between 1995 and 1998 who participated in a multiethnic, prospective cohort study. Women were followed through December, 2012. We evaluated associations between log-transformed analytes and breast cancer-specific and all-cause mortality fitting multivariable Cox proportional hazards models. Over a median of 14.5 years of follow-up, 102 deaths occurred; 43 of these were due to breast cancer. In models adjusted for ethnicity/study site, age, body mass index, and tumor stage, increased levels of log-transformed SHBG were associated with reduced risk of both breast cancer-specific mortality (hazard ratio, HR 0.48; 95 % confidence interval, CI 0.26–0.89) and all-cause mortality (HR 0.64, 95 % CI 0.43–0.97). There were no associations between levels of estradiol, estrone, or testosterone for either endpoint. In subgroup analyses, after correction for multiple testing, increased estrone was significantly associated with reduced risk for breast cancer-specific mortality among participants with ER-negative tumors (HR 0.16, 95 % CI 0.05–0.63) but not among participants with ER-positive tumors. Increased serum levels of SHBG were associated with decreased risk of breast cancer-specific and all-cause mortality in women with breast cancer. These results should be confirmed in larger breast cancer survivor cohorts.

Keywords

Breast cancer Mortality Sex steroid hormones 

Abbreviations

SHBG

Sex steroid hormone-binding globulin

ER

Estrogen receptor

PR

Progesterone receptor

HEAL

Health, eating, activity, and lifestyle study

SEER

Surveillance, epidemiology, and end results

HR

Hazard ratio

HRT

Hormone replacement therapy

CI

Confidence interval

Notes

Acknowledgments

We would like to thank the HEAL participants for their dedication to this study

Funding

National Cancer Institute (N01-CN-75036-20, N01-CN-05228, N01-PC-67010, U54-CA116847, U54CA116848, R25-CA94880); National Institutes of Health (M01-RR-00037); University of New Mexico (NCRR M01-RR-0997); National Institute of Child Health and Human Development (N01-HD-3-3175); California Department of Health Services (050Q-8709-S1528).

Compliance with ethical standards

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

Ethical Statement

This study was performed with the approval of the Institutional Review Boards of participating centers in accordance with assurances filed with and approved by the U.S. Department of Health and Human Services.

References

  1. 1.
    Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616CrossRefPubMedGoogle Scholar
  2. 2.
    Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M, Lane D, Rodabough R, Gilligan M, Cyr M, Thomson C, Khandekar J, Petrovitch H, McTiernan A, Investigators W (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA J Am Med Assoc 289(24):3243–3253CrossRefGoogle Scholar
  3. 3.
    Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT, Investigators WHI (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA J Am Med Assoc 295(14):1647–1657. doi: 10.1001/jama.295.14.1647 CrossRefGoogle Scholar
  4. 4.
    Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical O (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi: 10.1200/jco.2009.26.3756 CrossRefPubMedGoogle Scholar
  5. 5.
    Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP, Women’s Healthy E, Living Study G (2008) Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 17(3):614–620. doi: 10.1158/1055-9965.epi-07-0761 PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A, Berselli E, Muti P, Secreto G (2005) Serum testosterone levels and breast cancer recurrence. Int J Cancer 113(3):499–502. doi: 10.1002/ijc.20582 CrossRefPubMedGoogle Scholar
  7. 7.
    Lonning P, Helle S, Johannessen D, Ekse D, Aldercreutz H (1996) Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Br Cancer Res Treat 39:335–341CrossRefGoogle Scholar
  8. 8.
    McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961–1966PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16(6):801–810CrossRefPubMedGoogle Scholar
  10. 10.
    Ma H, Sullivan-Halley J, Smith AW, Neuhouser ML, Alfano CM, Meeske K, George SM, McTiernan A, McKean-Cowdin R, Baumgartner KB, Ballard-Barbash R, Bernstein L (2011) Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report. BMC Complement Altern Med 11:109. doi: 10.1186/1472-6882-11-109 PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Doria-Rose VP, Marcus PM (2009) Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. Lung Cancer 63(2):295–300PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Engel LW, Strauchen JA, Chiazze L Jr, Heid M (1980) Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases. Am J Epidemiol 111(1):99–112PubMedGoogle Scholar
  13. 13.
    Cox DR (1972) Regression models and life tables (with discussion). JR Stat Soc B 34:187–220Google Scholar
  14. 14.
    Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Veronesi U, Formelli F (2007) Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 25(19):2685–2690. doi: 10.1200/jco.2006.09.0118 CrossRefPubMedGoogle Scholar
  15. 15.
    Kaaks R, Rinaldi S, Key TJ et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082CrossRefPubMedGoogle Scholar
  16. 16.
    He XY, Liao YD, Yu S, Zhang Y, Wang R (2015) Sex hormone binding globulin and risk of breast cancer in postmenopausal women: a meta-analysis of prospective studies. Horm Metab Res 47(7):485–490. doi: 10.1055/s-0034-1395606 CrossRefPubMedGoogle Scholar
  17. 17.
    Fortunati N, Becchis M, Catalano MG, Comba A, Ferrera P, Raineri M, Berta L, Frairia R (1999) Sex hormone-binding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells. J Steroid Biochem Mol Biol 69(1–6):473–479CrossRefPubMedGoogle Scholar
  18. 18.
    Kahn SM, Li YH, Hryb DJ, Nakhla AM, Romas NA, Cheong J, Rosner W (2008) Sex hormone-binding globulin influences gene expression of LNCaP and MCF-7 cells in response to androgen and estrogen treatment. Adv Exp Med Biol 617:557–564. doi: 10.1007/978-0-387-69080-3_57 CrossRefPubMedGoogle Scholar
  19. 19.
    Fazzari A, Catalano MG, Comba A, Becchis M, Raineri M, Frairia R, Fortunati N (2001) The control of progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone-binding globulin (SHBG). Mol Cell Endocrinol 172(1–2):31–36CrossRefPubMedGoogle Scholar
  20. 20.
    Catalano MG, Frairia R, Boccuzzi G, Fortunati N (2005) Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells. Mol Cell Endocrinol 230:31–37CrossRefPubMedGoogle Scholar
  21. 21.
    Fortunati N, Catalano MG (2006) Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells. Horm Metab Res 38(4):236–240CrossRefPubMedGoogle Scholar
  22. 22.
    Fortunati N, Catalano MG, Boccuzzi G, Frairia R (2010) Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 316(1):86–92. doi: 10.1016/j.mce.2009.09.012 CrossRefPubMedGoogle Scholar
  23. 23.
    Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, Malone KE, Strom BL, Ursin G, Marchbanks PA, McDonald JA, Spirtas R, Press MF, Bernstein L (2009) Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 18(8):2214–2220. doi: 10.1158/1055-9965.epi-09-0301 PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Catherine Duggan
    • 1
    Email author
  • Frank Stanczyk
    • 2
  • Kristin Campbell
    • 3
  • Marian L. Neuhouser
    • 1
  • Richard N. Baumgartner
    • 4
  • Kathy B. Baumgartner
    • 4
  • Leslie Bernstein
    • 5
  • Rachel Ballard
    • 6
  • Anne McTiernan
    • 1
    • 7
  1. 1.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of Obstetrics, Gynecology, and Preventive Medicine, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Faculty of MedicineUniversity of British ColumbiaVancouverCanada
  4. 4.Department of Epidemiology and Population Health, School of Public Health and Information Sciences, James Graham Brown Cancer CenterUniversity of LouisvilleLouisvilleUSA
  5. 5.Department of Population Sciences, Division of Cancer EtiologyBeckman Research Institute of the City of HopeDuarteUSA
  6. 6.Office of Disease PreventionNational Institutes of HealthBethesdaUSA
  7. 7.University of Washington Schools of Public Health and MedicineSeattleUSA

Personalised recommendations